Kuitunen A, Hiippala S, Vahtera E, Rasi V, Salmenperä M
Department of Anesthesiology and Intensive Care Medicine, Helsinki University Central Hospital, Helsinki, Finland.
Acta Anaesthesiol Scand. 2005 Oct;49(9):1272-9. doi: 10.1111/j.1399-6576.2005.00809.x.
Thrombin formation during cardiac surgery could result in disordered hemostasis and thrombosis. The aim of the study was to examine the effects of aprotinin and tranexamic acid on thrombin generation and fibrinolytic activity in patients undergoing cardiac surgery.
Data were collected prospectively from 60 patients undergoing coronary artery bypass grafting using cardiopulmonary bypass (CPB). In a randomized sequence, 20 patients received aprotinin, 20 patients received tranexamic acid, and in 20 patients placebo was used.
Significant thrombin activity was found in all the studied patients. Thrombin generation was less in the aprotinin group than in the tranexamic acid and the placebo group (thrombin/anti-thrombin III complexes 33.7 +/- 3.6, 53.6 +/- 7.0 and 44.2 +/- 5.3 microg/l 2 h after CPB and F1 + 2 fragment 1.50 +/- 0.10, 2.37 +/- 0.37 and 2.04 +/- 0.20 nmol/l 6 h after surgery, respectively). The inhibition of fibrinolysis was significant with both anti-fibrinolytic drugs (D-dimers 0.427 +/- 0.032, 0.394 +/- 0.039 and 2.808 +/- 0.037 mg/l 2 h after CPB, respectively). The generation of d-dimers was inhibited until 16 h after CPB in the aprotinin group. The plasminogen activation was significantly less in the aprotinin group (plasmin/anti-plasmin complexes 0.884 +/- 0.095, 2.764 +/- 0.254 and 1.574 +/- 0.185 mg/l 2 h after CPB, respectively).
Thrombin formation is inevitable in coronary artery bypass surgery when CPB is used. The suppression of fibrinolytic activity, either with aprotinin or with tranexamic acid interferes with the hemostatic balance as evaluated by biochemical markers. Further investigations are needed to define the role of hemostatic activation in ischemic complications associated with cardiac surgery.
心脏手术期间凝血酶的形成可能导致止血和血栓形成紊乱。本研究的目的是探讨抑肽酶和氨甲环酸对心脏手术患者凝血酶生成及纤溶活性的影响。
前瞻性收集60例行体外循环冠状动脉搭桥术患者的数据。按随机顺序,20例患者接受抑肽酶,20例患者接受氨甲环酸,20例患者使用安慰剂。
所有研究患者均发现有显著的凝血酶活性。抑肽酶组的凝血酶生成低于氨甲环酸组和安慰剂组(体外循环后2小时凝血酶/抗凝血酶III复合物分别为33.7±3.6、53.6±7.0和44.2±5.3μg/L,术后6小时F1 + 2片段分别为1.50±0.10、2.37±0.37和2.04±0.20nmol/L)。两种抗纤溶药物均显著抑制纤溶(体外循环后2小时D - 二聚体分别为0.427±0.032、0.394±0.039和2.808±0.037mg/L)。抑肽酶组D - 二聚体生成在体外循环后16小时仍受抑制。抑肽酶组纤溶酶原激活显著减少(体外循环后2小时纤溶酶/抗纤溶酶复合物分别为0.884±0.095、2.764±0.254和1.574±0.185mg/L)。
使用体外循环时,冠状动脉搭桥手术中凝血酶形成不可避免。用抑肽酶或氨甲环酸抑制纤溶活性会干扰止血平衡,这可通过生化标志物评估。需要进一步研究以确定止血激活在心脏手术相关缺血性并发症中的作用。